159 related articles for article (PubMed ID: 30124353)
21. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
Haaß W; Kleiner H; Weiß C; Haferlach C; Schlegelberger B; Müller MC; Hehlmann R; Hofmann WK; Fabarius A; Seifarth W; ;
PLoS One; 2015; 10(6):e0129648. PubMed ID: 26087013
[TBL] [Abstract][Full Text] [Related]
22. The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia.
Islamagic E; Hasic A; Kurtovic S; Suljovic Hadzimesic E; Mehinovic L; Kozaric M; Kurtovic-Kozaric A
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):238-240. PubMed ID: 28283298
[TBL] [Abstract][Full Text] [Related]
23. Predictive parameters for imatinib failure in patients with chronic myeloid leukemia.
Lekovic D; Gotic M; Milic N; Zivojinovic B; Jovanovic J; Colovic N; Milosevic V; Bogdanovic A
Hematology; 2017 Sep; 22(8):460-466. PubMed ID: 28327053
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic Drug Monitoring of Imatinib and N-Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC-MS/MS in a Cohort Study.
Huang X; Liu Y; Chen J; Zheng H; Ding Y; He Z
J Clin Pharmacol; 2023 Dec; 63(12):1438-1447. PubMed ID: 37563838
[TBL] [Abstract][Full Text] [Related]
25. Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.
Stella S; Tirró E; Massimino M; Vitale SR; Russo S; Pennisi MS; Puma A; Romano C; DI Gregorio S; Innao V; Stagno F; DI Raimondo F; Musolino C; Manzella L
In Vivo; 2019; 33(5):1593-1598. PubMed ID: 31471409
[TBL] [Abstract][Full Text] [Related]
26. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.
Sohn SK; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Yoon SS; Kim H; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Moon JH; Park SY
Leuk Lymphoma; 2011 Jun; 52(6):1024-9. PubMed ID: 21463107
[TBL] [Abstract][Full Text] [Related]
27. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
28. Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib.
Qin YZ; Jiang Q; Lai YY; Jiang H; Shi HX; Zhao XS; Liu YR; Huang XJ
Leuk Lymphoma; 2017 Jun; 58(6):1384-1393. PubMed ID: 27733081
[TBL] [Abstract][Full Text] [Related]
29. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
[TBL] [Abstract][Full Text] [Related]
30. Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center.
Dou X; Qin Y; Lai Y; Shi H; Huang X; Jiang Q
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):e304-e315. PubMed ID: 32209331
[TBL] [Abstract][Full Text] [Related]
31. First report of imatinib measurement in hair: Method development and preliminary evaluation of the relation between hair and plasma concentrations with therapeutic response in chronic myeloid leukemia.
Capron A; Antunes MV; Wagner SC; Mattevi VS; Vieira N; Leite R; Reginato F; Capra M; Fogliatto L; Wallemacq P; Linden R
Clin Chim Acta; 2016 Jan; 453():42-7. PubMed ID: 26657979
[TBL] [Abstract][Full Text] [Related]
32. Correlation of plasma trough levels of imatinib with molecular response in patients with chronic myeloid leukemia.
Malhotra H; Sharma P; Bhargava S; Rathore OS; Malhotra B; Kumar M
Leuk Lymphoma; 2014 Nov; 55(11):2614-9. PubMed ID: 24446903
[TBL] [Abstract][Full Text] [Related]
33. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
[TBL] [Abstract][Full Text] [Related]
34. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
[TBL] [Abstract][Full Text] [Related]
35. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
Lin HX; Sjaarda J; Dyck J; Stringer R; Hillis C; Harvey M; Carter R; Ainsworth P; Leber B; Pare G; Sadikovic B
Eur J Haematol; 2016 Apr; 96(4):360-6. PubMed ID: 26059983
[TBL] [Abstract][Full Text] [Related]
36. Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib.
Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
Med Oncol; 2015 Aug; 32(8):213. PubMed ID: 26143137
[TBL] [Abstract][Full Text] [Related]
37. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
38. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
[TBL] [Abstract][Full Text] [Related]
39. Pharmacology and pharmacokinetics of imatinib in pediatric patients.
Suttorp M; Bornhäuser M; Metzler M; Millot F; Schleyer E
Expert Rev Clin Pharmacol; 2018 Mar; 11(3):219-231. PubMed ID: 29076384
[TBL] [Abstract][Full Text] [Related]
40. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]